Psychiatry and Neurology, Neurology · San Francisco, CA
NPI
1457372823
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
2324 Sacramento St Ste 111
San Francisco, CA, 94115
Phone (415) 600-3604
Groups this clinician bills Medicare through
Medicare paid, 2024
$93K
785 services
Medicare patients, 2024
339
Average age 74
Drug cost, 2024
$6.4M
1,114 prescriptions
Company payments, 2025
$56K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jonathan Katz was code 99215 (office e&m - established), 225 times for 149 patients. In total Jonathan Katz billed 785 services in 28 codes, and Medicare paid $93K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-03-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 225 | 149 | $153.03 | $34K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 115 | 74 | $14.27 | $1,642 |
| 99205 Office E&M - New | Office | 73 | 73 | $185.00 | $14K |
| 99214 Office E&M - Established | Office | 61 | 55 | $109.25 | $6,664 |
| 95886 Electrical Nerve Conductivity | Office | 46 | 42 | $98.78 | $4,544 |
| 99204 Office E&M - New | Office | 32 | 32 | $148.21 | $4,743 |
| 95912 Electrical Nerve Conductivity | Office | 29 | 29 | $244.44 | $7,089 |
| 92507 Speech Therapy | Office | 23 | 11 | $53.86 | $1,239 |
| 99223 Hospital E&M - Initial | Facility | 22 | 22 | $144.51 | $3,179 |
| 92526 Speech Therapy | Office | 21 | 11 | $72.10 | $1,514 |
| 95911 Electrical Nerve Conductivity | Office | 17 | 17 | $209.86 | $3,568 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 16 | 15 | $29.34 | $469 |
| 99203 Office E&M - New | Office | 16 | 16 | $91.50 | $1,464 |
| 95908 Electrical Nerve Conductivity | Office | 14 | 14 | $106.04 | $1,485 |
| 99213 Office E&M - Established | Office | 11 | 11 | $78.75 | $866 |
By year: 2022 $73K for 563 services; 2023 $85K for 631 services; 2024 $93K for 785 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jonathan Katz prescribed most often to Medicare patients was Radicava Ors (Edaravone), with 150 prescriptions and refills. In total Jonathan Katz wrote 1,114 Medicare prescriptions that cost $6.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Radicava Ors Edaravone | 150 | 150 | 20 | $2.1M |
| Riluzole Generic | 127 | 223 | 31 | $24K |
| Gabapentin Generic | 121 | 173 | 31 | $1,996 |
| Prednisone Generic | 92 | 132 | 18 | $634 |
| Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 | 68 | 68 | Under 11 | $471K |
| Gamunex-C Immune Globul G/Gly/Iga Avg 46 | 57 | 59 | Under 11 | $615K |
| Azathioprine Generic | 43 | 96 | 12 | $13K |
| Mycophenolate Mofetil Generic | 43 | 67 | Under 11 | $3,507 |
| Privigen Immun Glob G(Igg)/Pro/Iga 0-50 | 31 | 31 | Under 11 | $555K |
| Evrysdi Risdiplam | 25 | 27 | Under 11 | $789K |
| Relyvrio Sod Phenylbutyrat/Taurursodiol | 24 | 24 | Under 11 | $299K |
| Levetiracetam Generic | 21 | 45 | Under 11 | $1,131 |
| Nortriptyline Hcl Generic | 19 | 25 | Under 11 | $116 |
| Pyridostigmine Bromide Generic | 17 | 25 | Under 11 | $1,095 |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 16 | 16 | Under 11 | $128K |
Brand drugs: - claims; generic drugs: 701 claims; opioid claims: 11.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jonathan Katz $56K ($56K in general payments such as food, travel and fees) from 16 companies. The largest payer was Janssen Research & Development, LLC with $16K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Research & Development, LLC JNJ | 1 | $16K |
| Grifols USA, LLC | 10 | $13K |
| Novavax Inc NVAX | 1 | $11K |
| Genzyme Corporation SNY | 1 | $10K |
| Amgen Inc. AMGN | 3 | $3,513 |
| Grifols Shared Services North America, Inc. | 1 | $2,100 |
| Argenx US, Inc. ARGX | 8 | $396 |
| Pfizer Inc. PFE | 1 | $89.3 |
| Tanabe Pharma America, Inc. | 3 | $63.89 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $40.59 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.